Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multi-institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jung Kwon | - |
dc.contributor.author | Kim, Sung Han | - |
dc.contributor.author | Song, Mi Kyung | - |
dc.contributor.author | Joo, Jungnam | - |
dc.contributor.author | Seo, Seong Il | - |
dc.contributor.author | Kwak, Cheol | - |
dc.contributor.author | Jeong, Chang Wook | - |
dc.contributor.author | Song, Cheryn | - |
dc.contributor.author | Hwang, Eu Chang | - |
dc.contributor.author | Seo, Ill Young | - |
dc.contributor.author | Lee, Hakmin | - |
dc.contributor.author | Hong, Sung-Hoo | - |
dc.contributor.author | Park, Jae Young | - |
dc.contributor.author | Chung, Jinsoo | - |
dc.date.accessioned | 2021-09-01T16:52:16Z | - |
dc.date.available | 2021-09-01T16:52:16Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/66418 | - |
dc.description.abstract | Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein. Materials and Methods From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS). Results The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median first-line PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p= 0.005); 10, 7, and 3 months (p= 0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS. Conclusion The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.subject | TARGETED THERAPY | - |
dc.subject | OPEN-LABEL | - |
dc.subject | SURVIVAL | - |
dc.subject | VALIDATION | - |
dc.subject | CRITERIA | - |
dc.subject | TUMORS | - |
dc.title | Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multi-institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Jae Young | - |
dc.identifier.doi | 10.4143/crt.2018.421 | - |
dc.identifier.scopusid | 2-s2.0-85064495289 | - |
dc.identifier.wosid | 000464009400034 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.51, no.2, pp.758 - 768 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 51 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 758 | - |
dc.citation.endPage | 768 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002456197 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TARGETED THERAPY | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | CRITERIA | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordAuthor | Non-clear cell | - |
dc.subject.keywordAuthor | Metastatic renal cell carcinoma | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Criteria | - |
dc.subject.keywordAuthor | Validation | - |
dc.subject.keywordAuthor | Korean | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.